H.C. Wainwright analyst Edward White initiated coverage of Avalo Therapeutics (AVTX) with a Neutral rating and no price target The firm says the company’s AVTX-009 has promise to treat inflammatory diseases. The analyst waits for the initial hidradenitis suppurativa data and for the company to progress further along with the Phase 2 study.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio